ArticleESC heart failure2022
Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan.
Article in ESC heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 19 citations in OpenAlex.
- Sacubitril/Valsartan Improves Functional Capacity and Reverses LV Remodeling in Obese Patients with Hypertrophic HFpEF: A Randomized Open-Label Study.Journal of clinical medicine · 2026Article
- Long-term outcomes following sacubitril/valsartan therapy for chronic HFrEF: an Italian real-world multicentre study.ESC heart failure · 2026Article
- Prediction of recurrent heart failure hospitalizations and mortality using the echocardiographic Killip score.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- Evaluation of the 6-Month Effect of Sacubitril-Valsartan Compared to ACEI and ARB on LVEF in Heart Failure Patients: A Double-Blind Randomized Clinical Trial.Journal of pharmacy & bioallied sciences · 2025Article
- The effects of Dapagliflozin in a real-world population of HFrEF patients with different hemodynamic profiles: worse is better.Cardiovascular diabetology · 2024Observational
- Current Review of Heart Failure-Related Risk and Prognostic Factors.Biomedicines · 2024Review
- Vericiguat in heart failure with reduced ejection fraction: hope or solid reality?Heart failure reviews · 2024Review
- Effect of sacubitril/valsartan on cardiac remodeling compared with other renin-angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples.Clinical research in cardiology : official journal of the German Cardiac Society · 2024Article
- Article
- Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan.ESC heart failure · 2023Article
- The Long-Term Benefit of Sacubitril/Valsartan in Patients with HFrEF: A 5-Year Follow-Up Study in a Real World Population.Journal of clinical medicine · 2023Article
- Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan.ESC heart failure · 2022Article
- Assessing clinical and biomarker characteristics to optimize the benefits of sacubitril/valsartan in heart failure.Frontiers in cardiovascular medicine · 2022Review
- Effect of Sacubitril-Valsartan on Restoration and Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation.Frontiers in cardiovascular medicine · 2022Article
- Prognostic significance of resting cardiac power to left ventricular mass and E/e' ratio in heart failure with preserved ejection fraction.Frontiers in cardiovascular medicine · 2022Article
- Effects of sacubitril/valsartan on renal function and outcome in patients with heart failure and reduced ejection fraction: an Italian cohort study.Therapeutic advances in cardiovascular diseaseObservational
Corrections and comments
- Erratum issued
Authors and funding
26 authors at 12 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimEcho-derived haemodynamic classification, based on forward-flow and left ventricular (LV) filling pressure (LVFP) correlates, has been proposed to phenotype patients with heart failure and reduced ejection fraction (HFrEF). To assess the prognostic relevance of baseline echocardiographically defined haemodynamic profile in ambulatory HFrEF patients before starting sacubitril/valsartan. METHODS AND
resultsIn our multicentre, open-label study, HFrEF outpatients were classified into 4 groups according to the combination of forward flow (cardiac index; CI:< or ≥2.0 L/min/m
conclusionsEchocardiographically-derived haemodynamic classification identifies ambulatory HFrEF patients with different risk profiles. In real-world HFrEF outpatients, sacubitril/valsartan is effective in improving outcome across different haemodynamic profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.